I Spy CPhI - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

I Spy CPhI


Pharmaceutical Technology Europe
Volume 23, Issue 9


Rich Whitworth
Summer can often feel like a quiet month for the pharma industry in Europe. With holidays taken by so many staff, business can be quiet and out-of-office notifications abound. But in autumn, the beast awakens from its slumber.

And it does so with a number of important events, of which CPhI is one of the biggest. Come October 25, almost 30000 people from over 140 countries will come together to network, discuss the latest industry trends and hopefully forge new partnerships.

In current economic times, such shows can seem a financial burden, but the opportunity to meet people face-to-face, for me, is becoming less frequent, and to have such large numbers from the industry all under one roof is a compelling enough reason to attend. But we are also at a time of great change, with a large number of increasingly hot topics: rise of generics, emerging markets, biosimilars and biobetters, supply chain security... the list goes on. Being able to talk with others in the industry not only gives us insight into where we are now, but also, more importantly, where we might be heading.

This year, the majority of the PTE team will be attending the show in Frankfurt at booth: 51F53. You are more than welcome to visit us to let us know what's happening in your corner of the market, or to tell us about something exciting you've seen. We will be active online, providing daily show blogs and feeding important news through our twitter account. If you're not already a follower, and especially if you're not able to attend the show but want to be kept up-to-date, then head to http://PharmTech.com/twitter to join us. All of our activities will also be highlighted on a special CPhI page at http://PharmTech.com/CPhI.

As always, you're free to contact me directly, by email, but hopefully we may have a chance to meet in person soon.

Best wishes,
Rich Whitworth
Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here